Enlarge / Dr. Peter Marks, director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, testifies during a Senate Health, Education, Labor, and Pensions Committee hearing on the federal coronavirus response on Capitol Hill in March 2021, in Washington, DC. (credit: Getty | Pool)

The US Food and Drug Administration's committee of independent vaccine experts gathered Thursday to discuss the future of COVID-19 shots. The meeting seemed primed for explosive debate. Earlier in the week, the FDA released documents that made clear the agency is holding steadfast to its idea that COVID vaccines will fit the mold of annual flu shots—with reformulations decided in the first half of each year, followed by fall rollouts in anticipation of winter waves.

But outside experts, including some on the FDA's advisory committee, have questioned almost every aspect of that plan—from the uncertain seasonality of COVID-19 so far, to the futility of chasing fast-moving variants (or subvariants, as the case may be). Some have even questioned whether there's a need to boost the young and healthy so frequently when current vaccines offer protection against severe disease, but only short-lived protection against infection.

One particularly outspoken member of FDA's committee, Paul Offit, a pediatrician and infectious disease expert at Children’s Hospital of Philadelphia, has publicly assailed the bivalent booster, writing a commentary piece in the New England Journal of Medicine earlier this month titled: Bivalent Covid-19 Vaccines — A Cautionary Tale. (The FDA's advisory committee voted 19-2 in support of the bivalent boosters last year, with Offit being one of the two votes against.)

Enlarge / Passengers wearing face masks wait to board a high-speed railway train in Guangzhou South railway station on January 15, 2023, in Guangzhou, China. China is currently experiencing Spring Festival travel season, where millions of Chinese travel around the country before celebrating the Chinese or Lunar New Year. (credit: Getty | Vernon Yuen/NurPhoto )

China is now reporting that nearly 60,000 people had died of COVID-19 since early December when the country abruptly abandoned its zero-COVID policy and omicron subvariants began ripping through its population. The new death toll is a stark revision from China's previously reported figure for that period, which was just 37. But experts remain skeptical that the new, much larger tally is a complete accounting, and the World Health Organization continues to press the country to release more data.

In a Saturday press conference in Beijing, the Medical Administration Director of China's National Health Commission (NHC), Jiao Yahui, told reporters that the country recorded 59,938 COVID-related deaths between December 8 and January 12. Of those, 5,503 deaths were specifically linked to respiratory failure, and 54,435 were associated with underlying conditions, such as cancer and cardiovascular disease.

The new figures double the country's tally of COVID-19 deaths due specifically to COVID-19 respiratory failure, bringing the pandemic total to 10,775. Previously, those deaths—the ones due to COVID-19 respiratory failure or pneumonia—were the only deaths that China counted as caused by COVID-19, which drew criticism from WHO officials, who called the classification "too narrow."